Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Advances in the treatment of Wilson’s disease

Prashanth Kukkle, PhD, Center for Parkinson’s Disease and Movement Disorders Clinic Vikram Hospitals, Bangalore, India, discusses the progress made in the diagnosis and treatment of Wilson’s Disease, a genetic disorder characterized by copper accumulation in the body. Previously considered an untreatable disease, advancements in research and therapies have led to improved outcomes and a near-normal quality of life for patients. Various de-coppering medications, such as penicillamine and trientine, have been used to address copper buildup. Liver transplantations and emerging neurotherapies show promise for better patient outcomes. Recognizing the different mutations and presentations of Wilson’s Disease, such as early or late onset and varying symptoms like jaundice or neurological issues, is crucial. New technologies, including CRISPR and vector-based therapies, may offer targeted treatments based on genetic mutations. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.